IBA Dosimetry placed Frame Order for 2014

A frame order for the production of diode detectors has been signed. C-RAD and IBA Dosimetry have agreed upon deliveries until September 2014 worth 3,6 MSEK.

IBA Dosimetry is a world market leader of dosimetry products and systems for use in diagnostics and radiation therapy. The subsidiary C-RAD Imaging AB is since 1 January 2010 responsible for the manufacturing and the further development of the IBA diode detector program. The detectors are used for in-vivo dosimetry and calibration of accelerator systems.

C-RAD and IBA are at the moment discussing to stop the production at the C-RAD facility in Uppsala.

Tim Thurn, CEO, C-RAD AB:

“Following current trends in radiation therapy the demand of diode detectors is continuously decreasing. We have therefore decided to restructure our business and to focus our resources on the prosperous business with advanced products for patient positioning in radiation therapy.”

For further information:

Tim Thurn, CEO C-RAD AB, Phone +46-18-666947, E-mail investors@c-rad.com

The above information is price sensitive and must therefore be disclosed under the Securities Market Act (2077:528).

About C-RAD

C-RAD develops new and innovative solutions for the use in advanced radiation therapy. The company group of C-RAD offers products and solutions for patient positioning, tumor localization and radiation treatment systems. End users are radiation therapy clinics worldwide. All product development is conducted in three fully owned subsidiaries; C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB. C-RAD Imaging AB is located in Östersund while the other companies are located in Uppsala. Numbers of employees are currently 28 people. The activities in C-RAD AB originate from research and development at the Karolinska Institutet in Solna. Sales of the company’s first product, the C-RAD Sentinel^TM, started in 2007. Cooperation agreements have been signed with the Swedish company Elekta, the US company Varian  and the Belgian company IBA. C-RAD is represented by distributors specialized in radiation therapy on major markets. C-RAD has founded three companies for direct sales, C-RAD Incorporated in the US, C-RAD GmbH in Germany and C-RAD WOFE in China. C-RAD has invested in 29 % of the laser company Cyrpa and with an option to acquire the remaining 71 %. C-RAD AB is since March 2010 listed at Nasdaq Omx First North Premier. Erik Penser Bankaktiebolag is appointed as C-RAD’s Certified Adviser.

For more information on C-RAD, please visit www.c-rad.com.